Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Bruker’s ultrafleXtreme™ MALDI-TOF/TOF to be Coupled with Nextval’s MassInsight™ Technology

Published: Monday, February 11, 2013
Last Updated: Monday, February 11, 2013
Bookmark and Share
Collaboration between Bruker and Nextval for high-throughput screening of drugs.

Bruker has announced a collaboration between Bruker and Nextval for high-throughput screening of drugs and their metabolites using Bruker's ultrafleXtreme MALDI-TOF/TOF in conjunction with Nextval's MassInsight technology.

The ultrafleXtreme mass spectrometer combines the acquisition speed of its 2 kHz smartbeam II™ laser with its Perpetual Ion Source for unrivalled productivity, ensuring optimum performance for low concentration high-throughput screening.

The versatility of Bruker's Compass™ software allows integration with Nextval's screening technology to maximize sample density and reduce sample analysis costs.

Nextval's MassInsight screening technology is based on novel surface chemistries coupled with unique microarray acoustic deposition methods (EDC Biosystems & BioSero LLC) that address critical needs in several industries including the pharmaceutical, testing and industrial markets.

Dr. Matthew Greving, CSO of Nextval, stated: "The ultrafleXtreme is an invaluable tool for Nextval because it combines the sensitivity and throughput needed for our MassInsight customers, enabling fast accurate screening of potential drug candidates and enzyme activity."

Nextval recently has been awarded a Phase II SBIR grant to further develop and commercialize their MassInsight technology for high-throughput enzyme assays.

Dr. Paul Speir, Senior Vice President of Bruker Daltonics stated: "We are excited by the combination of Nextval's MassInsight technology with the information rich, high throughput capabilities provided by the ultrafleXtreme. Moreover, we are pleased to support Nextval in their efforts to develop this important technology for the rapid and economical screening of drug candidates."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Bruker Awarded Fourth PeakForce Tapping Patent
AFM mode uniquely combines highest resolution imaging and material property mapping.
Thursday, July 24, 2014
Novel Approach for Inborn Errors of Metabolism Screening by NMR
Clinical IEM-by-NMR screening study in Turkey measures 65 metabolites in urine simultaneously, including 20 endogeneous metabolites and 45 metabolites associated with inborn errors of metabolism.
Wednesday, September 04, 2013
Bruker and SAT Announce Joint Publication
Publication of study on SISCAPA-MALDI-TOF mass spectrometry for biomarker validation and clinical research.
Monday, April 23, 2012
Bruker Celebrates Double Award Win at Pittcon 2012
The new GC-MS platform from Bruker Chemical and Applied Markets (CAM) Division – SCION TQ™ – picked up two prestigious awards at last week’s Pittcon in Orlando, Florida.
Tuesday, March 20, 2012
Scientific News
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
Angina Drug Could Inform A New Strategy To Fight Cryptococcosis
A drug, more commonly used in the treatment of angina, could be the focus of a new strategy in fighting the fatal fungal infection cryptococcosis.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!